Correlation of Serum Magnesium and Lipid Parameters in Patients of Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.51985/Keywords:
Type 2 diabetes mellitus; serum magnesium; hypomagnesaemia; lipid profile; triglycerides; LDL cholesterol; HDL cholesterol; dyslipidaemia; HbA1c; insulin resistance.Abstract
Objective: To ascertain the relationship between serum magnesium and lipid parameters in type 2 diabetes mellitus patients. Study design and Settings: analytical study in the department of pathology Sheikh zayed Hospital, Rahim Yar Khan. Methodology: 100 adults were recruited by non-probability consecutive sampling with T2DM. The fasting venous blood serum magnesium, fasting plasma glucose, HbA1c, total cholesterol, triglycerides, HDL cholesterol and LDL cholesterol were taken. The level of association among serum magnesium and lipid parameters was determined through Pearson correlation and linear regression.
Results: Mean age was 53.2 +/- 9.1 years and 54% were male. The average serum magnesium was 1.71 +/- 0.29 mg/dL; 47 of them had suffered hypomagnesemia. There were strong negative associations observed between serum magnesium and total cholesterol (r=-0.41), triglycerides (r=-0.46), LDL cholesterol (r=-0.43) and HbA1c (r=-0.34) and a positive association between serum magnesium and HDL cholesterol (r=0.39), all p<0.001. Hypomagnesemic patients had increased triglycerides, LDL cholesterol, total cholesterol and HbA1c and decreased HDL cholesterol.
Conclusion: Reduced serum magnesium had a significant negative lipid profile connected with T2DM. Periodic magnesium monitoring could be employed to detect diabetic patients at increased cardiometabolic risk
Downloads
References
1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K,
Duncan BB, et al. IDF Diabetes Atlas: Global, regional and
country-level diabetes prevalence estimates for 2021 and
projections for 2045. Diabetes Res Clin Pract. 2022;183:
109119. doi:10.1016/j. diabres. 2021.109119.
2. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J,
Maruthur NM, et al. Management of hyperglycaemia in type
2 diabetes, 2022: a consensus report by the ADA and EASD.
Diabetologia. 2022;65(12):1925-1966. doi:10.1007/s00125-
022-05787-2.
3. American Diabetes Association Professional Practice
Committee. Cardiovascular disease and risk management:
Standards of care in diabetes-2024. Diabetes Care. 2024;47
(Suppl 1):S179-S218. doi:10.2337/dc24-S010.
4. Li W, Zhu X, Song Y, Fan L, Wu L, Kabagambe EK, et al.
Association of serum magnesium with insulin resistance and
type 2 diabetes among adults in China. Nutrients. 2022;14(9):
1799. doi:10.3390/nu14091799.
5. Oost LJ, Tack CJ, de Baaij JHF. Hypomagnesemia and
cardiovascular risk in type 2 diabetes. Endocr Rev. 2023;44(3):3
57-378. doi:10.1210/endrev/bnac028.
6. Asbaghi O, Moradi S, Nezamoleslami S, Moosavian SP,
Hojjati Kermani MA, Lazaridi AV, et al. The effects of
magnesium supplementation on lipid profile among type 2
diabetes patients: a systematic review and meta-analysis of
randomized controlled trials. Biol Trace Elem Res.
2021;199(3):861-873. doi:10.1007/s12011-020-02209-5.
7. Asbaghi O, Sadeghian M, Mozaffari-Khosravi H, Maleki V,
Shokri A, Yuzbashian E, et al. Effects of oral magnesium
supplementation on glycaemic control in patients with type
2 diabetes: a systematic review and dose-response metaanalysis of controlled clinical trials. Br J Nutr. 2022;128(10):
1924-1935. doi:10.1017/S0007114521005201.
8. Oost LJ, van der Heijden AA, Vermeulen EA, Bos C, Elders
PJM, Slieker RC, et al. Serum magnesium is inversely
associated with heart failure, atrial fibrillation, and
microvascular complications in type 2 diabetes. Diabetes
Care. 2021;44(8):1757-1765. doi:10.2337/dc21-0236.
9. Alswat K. Type 2 diabetes control and complications and
their relation to serum magnesium level. Arch Med Sci.
2022;18(2):307-313. doi:10.5114/aoms/102443.
10. Drenthen LCA, de Baaij JHF, Rodwell L, van Herwaarden
AE, Tack CJ, de Galan BE. Oral magnesium supplementation
does not affect insulin sensitivity in people with insulin-treated
type 2 diabetes and a low serum magnesium: a randomised
controlled trial. Diabetologia. 2024;67(1):52-61. doi:10. 1007
/s00125-023-06029-9.
11. Pitliya A, Vasudevan SS, Batra V, Patel MB, Desai A,
Nethagani S, et al. Global prevalence of hypomagnesemia in
type 2 diabetes mellitus: a comprehensive systematic review
and meta-analysis of observational studies. Endocrine.
2024;84(3):842-851. doi:10.1007/s12020-023-03670-7.
12. Abdullah M, Al-Mahbashi H, Al-Adimi M, Al-Hag S, AlAkwa A, Alharazi T, et al. Prevalence and determinants of
hypomagnesemia in type 2 diabetes mellitus: a retrospective
cross-sectional study from a resource-limited setting. Medicine
(Baltimore). 2025;104:e41856. doi:10.1097/MD.000000
0000041856.
13. Li W, Zhu X, Song Y, Fan L, Wu L, Kabagambe EK, et al.
Association of serum magnesium with insulin resistance and
type 2 diabetes among adults in China. Nutrients.
2022;14(9):1799. doi:10.3390/nu14091799.
14. Alswat K. Type 2 diabetes control and complications and
their relation to serum magnesium level. Arch Med Sci.
2022;18(2):307-313. doi:10.5114/aoms/102443.
15. Asbaghi O, Moradi S, Nezamoleslami S, Moosavian SP,
Hojjati Kermani MA, Lazaridi AV, et al. The effects of
magnesium supplementation on lipid profile among type 2
diabetes patients: a systematic review and meta-analysis of
randomized controlled trials. Biol Trace Elem Res. 2021;199(3)
:861-873. doi:10.1007/s12011-020-02209-5.
16. Oost LJ, Tack CJ, de Baaij JHF. Hypomagnesemia and
cardiovascular risk in type 2 diabetes. Endocr Rev. 2023;44(3):
357-378. doi:10.1210/endrev/bnac028.
17. Oost LJ, van der Heijden AA, Vermeulen EA, Bos C, Elders
PJM, Slieker RC, et al. Serum magnesium is inversely
associated with heart failure, atrial fibrillation, and
microvascular complications in type 2 diabetes. Diabetes
Care. 2021;44(8):1757-1765. doi:10.2337/dc21-0236.
18. Inacio I, Azevedo T, Balsa AM, Ferreira S, Rosinha P, Alves
M, et al. Association between serum magnesium and glycemic
control, lipid profile and diabetic retinopathy in type 1 diabetes.
Cureus. 2022;14(1):e21128. doi:10.7759/cureus.21128.
19. Asbaghi O, Sadeghian M, Mozaffari-Khosravi H, Maleki V,
Shokri A, Yuzbashian E, et al. Effects of oral magnesium
supplementation on glycaemic control in patients with type
2 diabetes: a systematic review and dose-response metaanalysis of controlled clinical trials. Br J Nutr. 2022;128(10)
:1924-1935. doi:10.1017/S0007114521005201.
20. Xu L, Chen X, Zhang W, Liao J, Wang Y, Chen Q, et al.
Effects of magnesium supplementation on improving
hyperglycemia, hypercholesterolemia and hypertension in
type 2 diabetes: an updated meta-analysis. Front Nutr.
2023;10:1128350. doi:10.3389/fnut.2023.1128350.
21. Drenthen LCA, de Baaij JHF, Rodwell L, van Herwaarden
AE, Tack CJ, de Galan BE. Oral magnesium supplementation
does not affect insulin sensitivity in people with insulin-treated
type 2 diabetes and a low serum magnesium: a randomised
controlled trial. Diabetologia. 2024;67(1):52-61. doi:10.
1007/s00125-023-06029-9.
22. Al Maqrashi N, Al Kiyumi MH, Al Ghafri T, Al Adawi S,
Al-Zakwani I, Al Busaidi N, et al. Effect of magnesium
supplements on improving glucose control, blood pressure
and lipid profile in patients with type 2 diabetes mellitus: a
systematic review and meta-analysis. Sultan Qaboos Univ
Med J. 2025;25(2):e173-e184. doi:10.18295/2075-0528.2848
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
